Q-omics provides the consensus-scored PPP1R3B profile across patient tissues and cancer cell-line models. PPP1R3B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PPP1R3B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PPP1R3B RNA expression shows 19,388 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, KIRC, and THYM as cancer lineages where PPP1R3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP1R3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP1R3B survival associations across molecular data types. PPP1R3B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP1R3B RNA expression–survival associations across cancer types. High PPP1R3B expression shows unfavorable associations in STAD, KIRP, PAAD, LGG and CESC, but favorable associations in UVM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for PPP1R3B RNA expression.
This table summarizes PPP1R3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PPP1R3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP1R3B shows lower tumor expression in LIHC and BLCA and higher tumor expression in KIRC, KIRP, LUAD and THCA. The KIRC box plot shows higher PPP1R3B RNA expression in tumor versus normal tissue (log2 FC = +1.803, t-test p < 0.001).
This table shows molecular features associated with PPP1R3B in patient tissues and cancer cell lines. In patient samples, PPP1R3B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP1R3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
